In 2023, Rraynex became the first Indian pharmaceutical company to integrate the complete process — intermediates, APIs, and pellet manufacturing — under one ecosystem.

This integration enhanced control, reduced handoffs, and ensured superior quality through end-to-end process validation and synchronized production lines.

It marked the start of a unified and efficient manufacturing system capable of handling complex global projects.

2024 marked Rraynex’s emergence as one of Western India’s largest pellet manufacturers.

The company commissioned a state-of-the-art GMP-certified facility and acquired a second unit dedicated to APIs and intermediates, reinforcing its operational scalability.

Process Analytical Technology (PAT) systems and automated coating lines were introduced to enhance precision, yield consistency, and product uniformity.

In 2025, Rraynex achieved WHO-GMP certification and validated an annual capacity of 125 metric tons of pellets and 30 metric tons of granules — establishing itself among India’s largest standalone pellet manufacturers.

It also earned ISO 9001, ISO 14001, and ISO 45001 certifications, reinforcing its global quality commitment and sustainability practices.

Within three years of incorporation, Rraynex filed three new product developments supported by stability data and Drug Master Files, expanding its portfolio to over 127 formulations.

That year, Rraynex was also recognized across leading international pharma exhibitions and publications for exceptional growth and innovation.

The roadmap for 2026 focuses on UGMP compliance, global registrations, and next-generation API development.

Expansion plans include reactor upgrades, pilot-scale R&D units, and digitized QMS systems to strengthen process control and sustainability under ISO 14001 guidelines.

Rraynex continues to evolve as a global partner in reliable, high-quality pharmaceutical manufacturing.